Changing survival of people with myeloma and end stage kidney disease: A cohort study using Australian and New Zealand dialysis and transplant registry 1963 –2013

ConclusionsThe proportion of people with myeloma and ESKD remains stable, but their survival has progressively improved in Australia and New Zealand. On starting ESKD treatment with myeloma, a 59 year old without diabetes on peritoneal dialysis can expect a 45% 5 year survival, where a 75‐year‐old diabetic on haemodialysis has 9% 5 year survival.
Source: Nephrology - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research